Medifast (MED) Tops Q4 EPS by 24c, Misses on Revenue; Offers Q1 Revenue Guidance
Tweet
Share
E-mail
Get Alerts MED Hot Sheet
Price: $10.70 --0%
EPS Growth %: -295.5%
Financial Fact:
Provision for income taxes: 2.95M
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: -295.5%
Financial Fact:
Provision for income taxes: 2.95M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Medifast (NYSE: MED) reported Q4 EPS of $0.10, $0.24 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $119 million versus the consensus estimate of $131.65 million.
GUIDANCE:
Medifast sees Q1 2025 revenue of $100-120 million, versus the consensus of $130.75 million.
For earnings history and earnings-related data on Medifast (MED) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
- AeroVironment (AVAV) Tops Q4 EPS by 36c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
